Fibroblast growth factor-2 regulates human cardiac myofibroblast-mediated extracellular matrix remodeling by Daniyil A Svystonyuk et al.
Svystonyuk et al. Journal of Translational Medicine  (2015) 13:147 
DOI 10.1186/s12967-015-0510-4RESEARCH Open AccessFibroblast growth factor-2 regulates human
cardiac myofibroblast-mediated extracellular
matrix remodeling
Daniyil A Svystonyuk†, Janet MC Ngu†, Holly EM Mewhort, Brodie D Lipon, Guoqi Teng, David G Guzzardi,
Getanshu Malik, Darrell D Belke and Paul WM Fedak*Abstract
Background: Tissue fibrosis and chamber remodeling is a hallmark of the failing heart and the final common
pathway for heart failure of diverse etiologies. Sustained elevation of pro-fibrotic cytokine transforming growth
factor-beta1 (TGFβ1) induces cardiac myofibroblast-mediated fibrosis and progressive structural tissue remodeling.
Objectives: We examined the effects of low molecular weight fibroblast growth factor (LMW-FGF-2) on human
cardiac myofibroblast-mediated extracellular matrix (ECM) dysregulation and remodeling.
Methods: Human cardiac biopsies were obtained during open-heart surgery and myofibroblasts were isolated,
passaged, and seeded within type I collagen matrices. To induce myofibroblast activation and ECM remodeling,
myofibroblast-seeded collagen gels were exposed to TGFβ1. The extent of ECM contraction, myofibroblast
activation, ECM dysregulation, and cell apoptosis was determined in the presence of LMW-FGF-2 and compared to its
absence. Using a novel floating nylon-grid supported thin collagen gel culture platform system, myofibroblast activation
and local ECM remodeling around isolated single cells was imaged using confocal microscopy and quantified by image
analysis.
Results: TGFβ1 induced significant myofibroblast activation and ECM dysregulation as evidenced by collagen gel
contraction, structural ECM remodeling, collagen synthesis, ECM degradation, and altered TIMP expression. LMW-FGF-2
significantly attenuated TGFβ1 induced myofibroblast-mediated ECM remodeling. These observations were similar using
either ventricular or atrial-derived cardiac myofibroblasts. In addition, for the first time using individual cells, LMW-FGF-2
was observed to attenuate cardiac myofibroblast activation and prevent local cell-mediated ECM perturbations.
Conclusions: LMW-FGF-2 attenuates human cardiac myofibroblast-mediated ECM remodeling and may prevent
progressive maladaptive chamber remodeling and tissue fibrosis for patients with diverse structural heart diseases.
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Structural cardiac remodeling with myocardial fibrosis is a
hallmark of progression to heart failure [1]. The cardiac
fibroblast maintains extracellular matrix (ECM) homeo-
stasis by balancing ECM production and turnover [2].
After myocardial infarction (MI), quiescent fibroblasts are
stimulated by the pro-fibrotic cytokine transforming* Correspondence: paul.fedak@gmail.com
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unless otherwise stated.growth factor (TGF)-β1 to become activated myofibro-
blasts [3-5]. Persistent myofibroblast activation leads to
ECM dysregulation with excessive ECM turnover resulting
in net ECM deposition and tissue fibrosis [6]. Myocardial
fibrosis is strongly associated with maladaptive post-MI
structural remodeling and clinical decompensation [7].
Clinical therapies aimed at preventing persistent myofi-
broblast activation in the post-MI heart may attenuate
maladaptive cardiac remodeling and improve clinical out-
comes [6,5].
Contemporary approaches to the surgical treatment of
the failing heart do not directly target myofibroblasttral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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are emerging such as injectable protein, gene, and cell
therapies that may be capable of directly targeting such
processes [8-11]. Identifying and validating key bioactive
proteins is critical to the development of these novel ap-
proaches. Specific bioactive proteins play an important
role in maintaining ECM homeostasis by regulating the
interaction between fibroblasts and their adjacent colla-
gen matrix [12]. We believe that such bioactive proteins
could be leveraged as effective therapeutic targets for pa-
tients at risk of cardiac remodeling and heart failure. We
previously showed that surgical cell transplantation in-
duced significant fibroblast growth factor (FGF)-2 ex-
pression in the post-MI myocardium that limited post-
MI maladaptive structural cardiac remodeling [10]. We
also found FGF-2 to be an effective anti-remodeling
therapy when used in a biosurgical approach with a low-
molecular weight FGF-2 (LMW-FGF-2) enhanced bio-
material surgically implanted on the epicardial surface of
the heart after MI [11]. These data and others suggest
that LMW-FGF-2, through its bioactive effects on ECM
homeostasis, may be a promising target as an anti-
remodeling strategy after MI.
LMW-FGF-2 is a multifunctional biopeptide known to
regulate numerous cellular processes that serve to main-
tain myocardial structure and function [13]. However,
LMW-FGF-2 is most recognized for its influence as a
potent angiogenic agent. The therapeutic application of
FGF-2 for cardiac ischemia to stimulate angiogenesis
was found to be safe but not clinically effective [14].
Interestingly, studies show that endogenous LMW-FGF-
2 may provide important cardioprotective effects in is-
chemic hearts without improving angiogenesis or tissue
perfusion [15,16]. These data may indicate that LMW-
FGF-2 could be best leveraged as an effective anti-
fibrotic therapy. However, the direct influence of LMW-
FGF-2 on cardiac myofibroblast-mediated fibrosis is not
well understood. In this study, for the first time, we pro-
vide a novel assessment of the effects of LMW-FGF-2
on human cardiac myofibroblast-mediated ECM remod-
eling using an innovative 3-dimensional (3D) in vitro
model.
Methods
Human cardiac myofibroblast isolation and expansion
Right atrial appendage and left ventricular apical myo-
cardial biopsies were obtained from consenting male and
female patients undergoing cardiac surgery using cardio-
pulmonary bypass at Foothills Medical Center (Calgary,
Alberta). All experiments involving human tissue were
approved by Conjoint Health Research Ethics Board at
the University of Calgary and conform to the Declar-
ation of Helsinki. Samples were minced and dissociated
in 0.2% Collagenase Type II at 37°C in an Isotemp® DryBath (Fisher Scientific) with gentle stirring. Myofibro-
blast cell suspension was collected and remnant tissue
was removed using a tissue strainer of 40 μm pore size
(BD Falcon™). Collected cells were centrifuged and the
cell pellet was subsequently seeded in complete medium
composed of Iscove’s Modified Dulbecco’s Medium
(IMDM) supplemented with 10% fetal bovine serum plus
50,000 units of penicillin and 50,000 μg of streptomycin.
Cells were cultured at 37°C with a 5% CO2 atmosphere.
Cells from passage 4–8 were used for these experiments.
The morphology of the cultured cells was consistent
with myofibroblasts as examined using phase-contrast
light microscopy. To further characterize the cells, im-
munocytochemistry was performed to confirm the pres-
ence of several fibroblast-specific markers: fibronectin,
vimentin, fibroblast surface protein and discoidin do-
main receptor-2. Greater than 95% of the cultured cells
from passage 4 stained positive for specific fibroblast
markers as previously described by our group [17].
Assessment of 3D collagen ECM remodeling
Cultured human cardiac myofibroblasts from passage
4–8 were serum-starved for 24 hours. Each experiment
utilized cells from the same passage. Myofibroblasts were
trypsinized and added to a liquid form of neutralized rat-
tail type I collagen (1.8 mg/mL, BD Biosciences) at high
density (2.5 × 105 cells/mL). Solutions were incubated at
37°C to allow for gel polymerization. Immediately after
polymerization, 500 μL of IMDM either alone (serum-free
medium [SFM]) or containing 10 ng/mL human recom-
binant TGF-β1 (Gibco-Invitrogen, Frederick MD), with or
without 20 ng/mL LMW-FGF-2 (Invitrogen, Camarillo,
CA, USA) was added to the culture wells and plates were
further incubated overnight. To initiate ECM contraction,
the cell-ECM constructs were released from the well wall
using a sterile micro-spatula (Corning®). Serial images of
the ECM dimensions were obtained from the time of re-
lease (baseline) and at 24 hours. ImageJ analysis software
(NIH, USA) was used to measure the area of ECM con-
traction as a quantitative measure of ECM remodeling.
Assessment of myofibroblast activation and ECM
remodeling in individual cells
We adapted a novel cell culture platform from Mohammadi
and co-workers that employs a floating thin collagen gel
supported by rigid nylon grids to isolated single cells within
3D collagen matrices [18]. Individual myofibroblasts were
assessed for cell activation (by morphology) and their local
effects on adjacent ECM remodeling by image analysis. In
brief, nylon screens with 200 × 200 μm openings (Dynamic
Aqua Supply, Surrey, BC) were cut into 2 × 2 cm squares.
Type I bovine dermal collagen (5.9 mg/mL, Advanced
Biomatrix, San Diego, CA) was diluted to a working concen-
tration of 1.0 mg/mL and neutralized to a pH=~7.4 using
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poured onto a parafilm-coated culture dish (hydrophobic
surface). Nylon squares were placed carefully on top of the
collagen, allowing for each grid opening to be filled with the
solution and incubated to ensure polymerization of the col-
lagen gel. Resultant collagen-coated constructs were gently
detached from the culture dish using warm PBS, inverted
and floated in serum-free IMDM culture medium ±10 ng/
mL human recombinant TGFβ1, with or without 20 ng/mL
LMW-FGF-2. Human cardiac myofibroblasts from the same
passage were seeded at low density (1 × 104 cells) allowing
single cells in each grid space. Treatments were maintained
for 24 hours.
Immunocytochemistry and confocal microscopy
After functional remodeling data were collected, the
cell-ECM constructs were immediately fixed in 4% PFA
at RT for 30 minutes. Constructs were then simultan-
eously blocked and permeabilized at RT for 1 hour by
incubating in blocking buffer containing 0.1% Triton® X-
100. Constructs were incubated in primary antibody
(mouse anti-α-SMA at 1:500, Sigma-Aldrich) for 48 hours,
washed and incubated in secondary antibody (Alexa Fluor®
488 goat anti-mouse at 1:500, Invitrogen) at RT for 1 hour
with gentle shaking. Lastly, constructs mounted onto
microscope glass slides in Prolong® Gold Antifade Reagent
containing DAPI for nuclear visualization. All fluorescent
images were captured using confocal laser microscopy
(LSM 5, Carl Zeiss) and processed using Zen software.
Cells positive for α-SMA were counted and divided by the
total DAPI (nuclei) for each image. α-SMA-positive cells
of 8 random images from each group were averaged and
expressed as a percentage (%) of the total cell number.
Collagen synthesis by [3H]-proline incorporation
To measure collagen synthesis, 1 μCi/mL [3H]-proline
was added to the supernatant treatment solution of the
collagen gels containing human cardiac myofibroblasts
from the same passage. After the functional ECM re-
modeling data was collected (48 hrs.), the collagen gels
were centrifuged and the extracellular proline was re-
moved by aspiration of the supernatant. Cells were lysed
and residual [3H]-proline in the collagen gels was re-
moved by incubating the cells for 5 minutes at room
temperature in 1 mL of a solution containing: 50 mM
Tris–HCl (pH 7.4), 150 mM NaCl, % Triton x-100,
0.5 % Sodium deoxycholate, 0.04% beta mercapto-
ethanol, 1 mM EDTA and centrifuging as above. The
collagen gels were dissolved in 0.4 N NaOH, and an ali-
quot of final solution was added to scintillation vials
containing 5 ml of Ecolite scintillation cocktail to deter-
mine [3H]-proline incorporated into protein (largely col-
lagen). Protein concentration was measured using the
Bradford assay. Nonspecific incorporation of [3H]-proline was defined as that observed in the presence of
an excess of unlabeled proline; or in collagen gels
formed without myofibroblasts.
In situ zymography
In situ zymography was modified for use in the collagen
gel contraction assay as we previously described [17]. In
brief, constructs containing human cardiac myofibro-
blasts from the same passage were prepared as described
in the previous section. DQT™ Gelatin-FITC (Molecular
Probes), which emits a quantifiable green fluorescent
signal when cleaved by proteases, was added to the li-
quid gel solution at a final concentration of 10 μg/mL
prior to gel polymerization. Subsequently, constructs
were fixed in 4% PFA for 30 minutes at RT, washed with
PBS, and mounted on microscope glass slides with Pro-
long Gold Antifade Reagent. Z-stack images from 8 ran-
dom fields of each collagen gel were captured using
confocal laser microscopy (LSM 5, Carl Zeiss) and images
were analyzed using Volocity software (PerkinElmer).
Bright green fluorescent spots indicating proteolytic diges-
tion in the acquired 3D gel image were identified as “green
fluorescent objects” on the Volocity software platform and
the total volume of these objects was summed as “Total
Volume of Green Fluorescence”. Mean fluorescence inten-
sity of each analyzed 3D gel image was generated auto-
matically by the Volocity software, by averaging the
fluorescence intensity of all the “green fluorescent objects”
identified in the image. The total green fluorescence activ-
ity, known to be proportionate to the total protease activ-
ity, was calculated by multiplying the total volume of
green fluorescence of each 3D image by its mean fluores-
cence intensity. The total protease activity in collagen gel
normalized to the corresponding 3D gel image volume to
allow for comparison between images:
Total Protease
Activity
¼ Mean Fluorescence Intensity  Total Volume of Green Fluorescence
Total Image Volume
Extraction of cells from ECM constructs
Cardiac myofibroblasts were harvested from the cell-
ECM constructs after the functional remodeling data
were collected. Cells were released by incubating the
constructs in 0.2% Collagenase Type II with constant
agitation until completely dissolved. The cell suspension
was centrifuged and the supernatant was discarded leav-
ing the cell pellet for further testing as described.
Flow cytometry
Cell pellets harvested from each collagen gel were re-
suspended in polystyrene round bottom 12 × 75 mm2
Falcon tubes. Cells were fixed in ice-cold methanol
at −20°C, followed by washing with PBS + 1% bovine
serum albumin (BSA). Cells were permeabilized by
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by centrifugation. Cells were stained with anti-α-SMA
conjugated with FITC (1:200 dilution; Sigma-Aldrich)
for flow cytometry analysis.
Cell apoptosis
Harvested cells pellets were resuspended in 1× Annexin
V binding buffer (BD Biosciences, Mississauga, ON)
with propidium iodide (1:100 dilution, BD Biosciences)
and FITC Annexin V (1:100 dilution, BD Biosciences)
before flow cytometry analysis.
Quantitative RT-PCR
Real-time PCR was performed on mRNA isolated, using
a Qiagen RNeasy extraction kit, from cardiac myofibro-
blasts extracted from the collagen gels. mRNA was con-
verted to cDNA for RT-PCR using Quantitect reverse
transcription kit (Qiagen, CA, USA). TIMP-1 and
TIMP-2 mRNA was quantified using human primer
pairs, TIMP-1 (forward: aattccgacctcgtcatcag; reverse:
tgcagttttccagcaatgag) & TIMP-2 (forward: tgatccaca-
cacgttggtct; reverse: tttgagttgcttgcaggatg), (University of
Calgary, DNA Lab Core Facility) and a Quantitect SYBR
Green PCR kit (Qiagen, CA, USA) and Bio-Rad Icycler.
Gene expression levels were measured against human
18 s RNA (Qiagen QuantiTect primer QT00199367) as
a housekeeping gene.
Luminex multiplex assay
Immediately following functional data collection within the
collagen gel contraction assay 50 μL of culture media was
collected from each well. The concentration of human
MMPs and TIMPs within the culture media was measured
using Luminex multiplex analysis (Eve Technologies,
Calgary, AB, Canada).
Assessment of cell morphology
Cells were fixed in 4% PFA and permeabilized in 0.1%
Triton-X. Myofibroblast actin cytoskeleton was marked
with Alexa Fluor 488 phalloidin (Life Technologies,
Burlington, ON) while cell nuclei were stained with
DAPI. Collagen fibers were imaged using confocal
reflectance microscopy (CRM) with a confocal laser
microscope (LSM 5, Carl Zeiss) as previously described
by our group [17]. Morphological parameters included
cell extension length and roundness (a dimensionless
shape factor). Cell extension length was measured from
the center of the cell to the tip of an extension using
ImageJ software (version 1.48, NIH, USA). Measurement
of roundness was performed using the Multi-Cell Outliner
plug-in for ImageJ (http://rsbweb.nih.gov/ij/plugins/multi-
cell-outliner.html). In brief, values approaching 1 are rep-
resentative of a round cell morphology while values ap-
proaching 0 are considered more non-round [19].Quantification of cell-mediated ECM remodeling
Assessment of collagen fiber alignment was performed
as described by Mohammadi and co-workers [18]. Colla-
gen fibers were imaged using confocal reflectance mi-
croscopy (CRM) with a confocal laser microscope (LSM
5, Carl Zeiss) as previously described by our group [17].
In brief, the Fast Fourier Transform (FFT) function of
ImageJ was used to quantify the distribution of collagen
fibers at a given angle from the acquired images. FFT
produces a spectral image in the frequency domain of
and orthogonal to the original intensity image [20]. To
quantify the directionality of the original image, pixel in-
tensities were summed along a straight line from the
image center at different angle intervals using the Oval
Profile ImageJ plug-in (http://rsb.info.nih.gov/ij/plugins/
oval-profile.html). An image in which the collagen fibers
are randomly distributed display relatively constant pixel
intensities at different angles. Orientation of collagen fi-
bers in a specific direction would correspond to higher
pixel intensities at that particular angle. From the result-
ant intensity curve, we define a collagen fiber alignment
index value by calculating the area under the curve
bound by the peak intensity value ± 10°.Statistical analysis
All group data are presented as mean ± SD. Data were
obtained from a representative experiment of which each
was repeated in triplicate. When only two groups were
compared, a Student’s t-test was performed. For com-
parison of more than two groups, one-way ANOVA was
used and followed by appropriate post hoc comparison
tests. All statistical analyses were performed using
GraphPad Prism 6.0, with p < 0.05 considered statisti-
cally significant.Results
LMW-FGF-2 prevents human cardiac myofibroblast-
mediated ECM remodeling
Cardiac myofibroblasts in vitro will remodel and contract
collagen matrices in proportion to the extent of their acti-
vation [21,22]. TGFβ1, a critical pro-fibrotic mediator of
human diseases, stimulates cardiac fibroblasts to undergo
phenotypic conversion into active myofibroblasts resulting
in collagen ECM remodeling and fibrosis [4]. Accordingly,
we examined the effects of exogenous LMW-FGF-2 on
TGFβ1-induced human cardiac myofibroblast-mediated
collagen remodeling (Figure 1). LMW-FGF-2 exposure
completely prevented TGFβ1-stimulated human cardiac
myofibroblast ECM remodeling as reflected by the attenu-
ation of TGFβ1-stimulated ECM contraction. Importantly,
both atrial and ventricular human cardiac myofibroblasts
stimulated with TGFβ1 demonstrated similar reductions
in ECM contraction in the presence of LMW-FGF-2.
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To confirm that the anti-fibrotic effect of LMW-FGF-2
is not a result of cell loss due to apoptosis, Annexin V
staining was performed for detection of externalized
apoptotic markers (phosphatidylserine). LMW-FGF-2
exposure did not induce apoptosis relative to TGFβ1
without LMW-FGF-2 exposure (1.10 ± 0.62% vs. 1.03 ±
0.61%, n = 3, p = ns), suggesting that the observed inhibi-
tory effects on collagen gel contraction were not a con-
sequence of cell apoptosis (data not shown in Figures).
LMW-FGF-2 inhibits TGFβ1-mediated myofibroblast
activation
The activation of myofibroblasts within ECM constructs
was assessed by immunostaining for α-SMA (Figure 2A)
with quantification by image analysis (Figure 2B). TGFβ1
stimulated α-SMA expression in human cardiac myofi-
broblasts within 3D collagen ECM constructs. The
addition of LMW-FGF-2 prevented α-SMA expression
increases with TGFβ1 exposure. Changes in α-SMA ex-
pression were also confirmed by flow cytometry using
cells extracted from the ECM constructs after ECM re-
modeling was initiated (Figure 2C). These data suggestFigure 1 Extracellular matrix remodeling by human cardiac myofibroblasts. T
mediated collagen gel contraction as compared to controls. This effect was in
from multiple individual experiments (4 experiments, total N = 14 per group f
normalized to the corresponding control groups. Bars represent mean ± SD; *that LMW-FGF-2 prevented myofibroblast activation in
response to TGFβ1 exposure.
LMW-FGF-2 attenuates TGFβ1-induced ECM dysregulation
ECM homeostasis requires a balance between ECM de-
position (synthesis) and ongoing degradation. Collagen
synthesis was assessed by [3H]-proline incorporation.
The pro-fibrotic peptide TGFβ1 induced a significant in-
crease in collagen synthesis, which was observed to de-
crease toward baseline in the presence of LMW-FGF-2
(Figure 3A). Excessive ECM turnover (dysregulation) re-
sults from imbalances between matrix protease activities
and their endogenous inhibitors, TIMPs. In situ zymo-
graphy was used to directly assess regional ECM prote-
ase activity within the collagen gel microenvironment
(Figure 3B). Indicative of ECM dysregulation and a pro-
pensity for structural remodeling, TGFβ1 increased total
protease activity within cell-ECM constructs. LMW-
FGF-2 abolished the TGFβ1-associated increases in pro-
tease activity. MMP concentrations in the conditioned
media of the TGF-β1 and LMW-FGF-2 groups (MMP-1,
MMP-2, MMP-7, MMP-9) were not significantly differ-
ent (data not shown). However, TGFβ1 profoundlyGFβ1 stimulates both atrial (A) and ventricular (B) myofibroblast-
hibited in the presence of LMW-FGF-2. Data presented were obtained
or A; 3 experiments, total N = 8 per group for B) and all values were
p < 0.01, **p < 0.001; abbreviation: CF – cardiac fibroblasts.
Figure 2 Effects of LMW-FGF-2 on myofibroblast activation. (A) Representative confocal microscopic images of cardiac myofibroblasts embedded
in a collagen gel, following treatments (control, TGFβ1 and LMW-FGF-2 + TGFβ1). Cells were stained for α-SMA (green) and nuclei (DAPI; blue).
(B) TGFβ1 increased α-SMA expression while LMW-FGF-2 diminished α-SMA expression. Bars represent mean ± SD; *p < 0.01. (C) α-SMA was
labeled with FITC-conjugated antibody and the intensity of a-SMA expression was measured using flow cytometry. TGFβ1 increased the cellular
expression of α-SMA and this effect was abolished by LMW-FGF-2.
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tein levels (Figures 3C-F) thereby increasing the capacity
for ECM turnover by reducing protease inhibition.
TIMP expression was partially restored to baseline by
the addition of LMW-FGF-2. These data collectively
indicate that LMW-FGF-2 attenuates TGFβ1-induced
ECM dysregulation.
LMW-FGF-2 attenuates TGFβ1-induced myofibroblast
morphologic changes
To better understand the role of LMW-FGF-2 on
myofibroblast activation and cell-induced remodeling,
a novel nylon-based thin fixed collagen grid was used
to study isolated cells and their local surrounding
collagen matrix. Unlike the previously describedcollagen gel contraction model, these thin gels permit
assessments of altered cell morphology and regional
matrix deformations without concomitant changes
in the collagen network surface area (compaction).
Validated morphological assessments were utilized
to study the extent of myofibroblast activation by
cytoplasmic extension length and roundness [18].
TGFβ1 stimulated myofibroblasts were observed to have
longer cell extensions and a more stellate morphology char-
acteristic of activated myofibroblasts (Figure 4). In con-
trast, LMW-FGF-2 treatment resulted in shorter cell
extensions and a round cell shape consistent with control
myofibroblast morphology (Figure 4E and F). Collec-
tively, these data suggest LMW-FGF-2 prevents activa-
tion of myofibroblasts.
Figure 3 ECM regulation by collagen synthesis, protease activity, and TIMP inhibition. (A) Collagen synthesis was assessed by measurement of 3H-proline
incorporation. TGFβ1 increased 3H-proline incorporation. This effect was abolished by addition of LMW-FGF-2. (B) ECM degradation was assessed by in situ
zymography using embedded DQ™ Gelatin-FITC to measure matrix proteolysis. Total protease activity was quantified as total fluorescent signal per image
volume. TGFβ1 increased total protease activity while LMW-FGF-2 attenuated this response. (C and D) Expression of TIMP-1 and TIMP-2, respectively, at the
mRNA levels are presented. TGFβ1 significantly reduced both TIMP-1 and TIMP-2 expression while LMW-FGF-2 partially restored expression. (E) At the
protein level, TGFβ1 did not alter TIMP-1, however the presence of LMW-FGF-2 resulted in increased TIMP-1 protein. (F) Though the results for TIMP-2 were
not statistically significant, a trend toward decreased TIMP-2 protein was noted in the TGFβ1 group and restored in the presence of LMW-FGF-2. *, p < 0.05.
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myofibroblast ECM remodeling
The cell-mediated remodeling of the local ECM was
assessed as a function of collagen fiber alignment at the
tips of cell extensions, as described by Mohammadi and
colleagues [18]. Collagen fibers preferentially align in the
direction of the underlying cell-induced strain field [23].
We assume that the extent of collagen fiber alignment isrelative to the strength of the strain field, which is a re-
flection of the magnitude of remodeling. Confocal re-
flectance microscopy was used to document changes in
matrix organization among the different treatment
groups. The collagen matrices in the absence of cells
consist of randomly oriented fibers with no directional
preference (Figure 4A). In contrast, the presence of in-
active myofibroblasts resulted in their partial orientation,
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to these controls, we observed significant ECM remodel-
ing following myofibroblast activation with TGFβ1 that
was lessened with LMW-FGF-2 treatment (Figure 4C
and D). These observations were simultaneously con-
firmed through Fast Fourier Transform (FFT) analysis,
showing that LMW-FGF-2 prevented the effects of
TGFβ1 such that the alignment index values approached
baseline levels (Figure 5A and B). These novel data con-
firm for the first time that LMW-FGF-2 attenuatesFigure 4 Myofibroblast morphology: extension length and
roundness. (A) Representative confocal images of single isolated
human cardiac myofibroblasts embedded into a thin collagen
nylon-based gel. Following treatments (control, TGFβ1, TGFβ1 +
LMW-FGF-2), cells were stained for F-actin (phalloidin; green) while
adjacent collagen matrix was visualized using confocal reflectance
(red). (B) Cell extension length was measured from the cell centroid
to the tip of a given cell extension. TGFβ1 increased mean cell
extension length while LMW-FGF-2 restored levels close to baseline.
Bars represent mean ± SD; *p < 0.05. (C) Roundness, a dimensionless
shape factor, was quantified for each treatment group. Values closer
to 1.0 represent round phenotypes while decreasing values <1.0 are
representative of a star-shaped phenotype (activated). TGFβ1
treatment favored a more stellate-cell shape while LMW-FGF-2
showed morphology consistent with non-activated cells. Bars
represent mean ± SD; *p < 0.05. Scale bar = 20 μm.TGFβ1-induced human myofibroblast-mediated ECM
remodeling.Discussion
Under pathological conditions, elevated levels of TGFβ1
have been well studied in stimulating the fibroblast-to-
myofibroblast transition [24]. Sustained myocardial
TGFβ1 activity in the post-MI heart drives persistent
myofibroblast activation and associated ECM dysregula-
tion resulting in maladaptive structural remodeling [4].
This study examined and validated the influence of
LMW-FGF-2 on human cardiac myofibroblast-mediated
ECM remodeling. Using a novel in vitro 3D model, we
validate for the first time that LMW-FGF-2 can prevent
TGFβ1-induced myofibroblast-mediated 3D extracellu-
lar matrix remodeling in cells from human cardiac
tissue. Our data show that LMW-FGF-2 attenuated
TGFβ1-induced changes in α-SMA expression, colla-
gen synthesis, and TIMP expression. These alterations
collectively reduced ECM turnover and prevented net
collagen accumulation (fibrosis) resulting in preserved
ECM architecture.
Fibrosis is a complex phenomenon. The role of LMW-
FGF-2 in mediating cardiac ECM regulation and fibrosis
pathways is unclear. Selected prior studies suggest that
cardiac FGF-2 expression is pro-fibrotic. Li and col-
leagues documented elevated FGF-2 in fibrotic human
atria inferring a pro-fibrotic causative role for FGF-2
[25]. In addition, Virag and co-workers detected greater
infarct scar formation after cardiac-specific over-
expression of FGF-2 in post-MI mutant mice [16]. In
contrast to these prior in vivo descriptive studies, our
data indicates a profound anti-fibrotic effect of LMW-
FGF-2 on human cardiac myofibroblasts within a 3D
collagen matrix. Our findings are consistent with the
work of others who observed that FGF-2 regulates
TGFβ1-mediated myofibroblast activity in non-cardiac
derived cells [26-29]. Furthermore, and in support of our
findings, Suzuki and co-workers documented an anti-
fibrotic effect with addition of exogenous FGF-2 to the
hearts of hypertensive rats [30]. To explain a possible
mechanism of action, Cushing and co-workers showed
that FGF-2 stimulates MAPK signaling and blocks the
localization of SMADs into the nucleus. The suppression
of SMADs normally upregulated by TGFβ1 prevented
the activation of genes that induce myofibroblast activity
and differentiation [31]. Although unproven, the ob-
served effects on ECM regulation (collagen synthesis,
degradation and TIMP expression) may be secondary
events to the suppression of myofibroblast activity by
LMW-FGF-2 exposure.
The molecular and cellular pathways that underlie car-
diac fibrosis and remodeling are complex and synergistic.
Figure 5 Extracellular matrix remodeling: collagen fiber alignment.
Collagen fiber alignment was assessed parallel to cell extensions as a
measure of cell-mediated ECM remodeling. (A) Normalized pixel intensity
curves generated from FFT analysis for each treatment group relative to
a no-cell control. Randomly oriented collagen fibers result in constant
pixel intensity at any given angle. Alignment of fibers parallel to cell
extensions result in increased intensity at certain angles. (B) Alignment
index is calculated by taking the area under the curve ± 10 degrees from
the maximum intensity value. TGFβ1 showed the greatest collagen fiber
alignment while LMW-FGF-2 attenuated this response. Bars represent
mean ± SD; *p < 0.05.
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distinct advantages over traditional cell culture experiments
that may allow for improved translation to the human con-
dition. First, we used cardiac myofibroblasts from human
atria and ventricles undergoing heart surgery. While we
recognize that differences in patient characteristics may
contribute to myofibroblast heterogeneity, the capacity to
induce expected changes through our treatment groups
was preserved. Second, we utilized an ECM composed of
type I collagen which is the primary isoform in the human
heart [32]. Third, we embedded the cells in 3D matrix
constructs. 3D matrices best mimic in vivo tissue microen-
vironments and permit normal physiologic cell-ECM inter-
actions [33]. Leveraging this knowledge, we confirmed
effects of LMW-FGF-2 on human cardiac myofibroblast-
mediated ECM remodeling using a novel cell culture plat-
form. This model may better reflect in vivo physiologic
conditions on account of its floating gel system with rigid lat-
eral boundaries that may mimic basement membranes [18].
Our recent studies have implicated LMW-FGF-2 as a
key paracrine mediator underlying the observed benefits
of cell transplantation in attenuating structural cardiac
remodeling [34,10,9]. Recently, we leveraged this cardio-
protective capacity using a unique LMW-FGF-2-en-
hanced biomaterial and found significant benefits on
preventing early post-MI maladaptive remodeling and fi-
brosis [11]. While this biomaterial showed favorable ef-
fects on the physiology of the post-MI heart, the effects
on endogenous cell populations remained poorly under-
stood. Spinale and co-workers recently examined the ef-
fects of myocardial injections of biocomposite materials
on myofibroblast activity in relation to LV remodeling
post-MI [8]. Growth factors and biomaterials are gaining
popularity over cell therapy approaches due to the bar-
riers to clinical translation with cell-based regenerative
approaches. Our data support the use of LMW-FGF-2
to directly target myofibroblast-mediated ECM remodel-
ing in the failing heart.
We believe that the present study substantiates the
anti-fibrotic influence of LMW-FGF-2 on human cardiac
myofibroblasts and demonstrates a proof-of-concept for
using LMW-FGF-2 to specifically target ECM dysregula-
tion in the post-MI human heart. When employed as a
Svystonyuk et al. Journal of Translational Medicine  (2015) 13:147 Page 10 of 11clinical therapy to induce angiogenesis, Ruel and Sellke
showed that FGF-2 delivery via sustained-release cap-
sules was proven to be safe for patients and effective at
increasing myocardial revascularization [35]. We specu-
late that LMW-FGF-2 is both safe and effective when
administered in patients at the time of post-MI remodel-
ing when TGFβ1 levels are increased, myofibroblasts are
activated, and ECM homeostasis is disturbed toward
myocardial fibrosis. Differences in fibrotic capacity have
been observed between atrial as compared to ventricular
cardiac myofibroblasts [36]. We confirmed an anti-
fibrotic response of LMW-FGF-2 on both atrial and
ventricular derived human cardiac myofibroblasts sug-
gesting that LMW-FGF-2 therapy could be effective at
limiting structural remodeling in both the atria and ven-
tricles in patients at risk of heart failure.
Conclusions
We uniquely demonstrated through two novel 3D cell
culture platforms the capacity of LMW-FGF-2 to attenu-
ate human cardiac myofibroblast activation and adjacent
ECM remodeling. This data may provide validation for
the use of LMW-FGF-2 in biosurgical approaches that
may prevent progressive maladaptive chamber remodel-
ing and tissue fibrosis for patients with diverse structural
heart diseases.
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